Cipla on Friday announced the launch of its proprietary respiratory inhalation therapy product ‘Niveoli’ in India. Niveoli addresses an unmet need associated with obstructive airway diseases such as asthma and chronic obstructive pulmonary disorder, Cipla said in a BSE filing. Shares of Cipla gained 1.84 per cent at ₹554.35 on the BSE.
Stocks
Company news: Cipla
|
Updated on
April 12, 2019
Published on
April 13, 2019
Published on
April 13, 2019
Company news: Cipla
|
Updated on
April 12, 2019
Published on
April 13, 2019
Published on
April 13, 2019